• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

RIPK3 Activates Parallel Pathways of MLKL-Driven Necroptosis and FADD-Mediated Apoptosis to Protect against Influenza A Virus

tetano

Editor, Senior Moderator
Cell Host Microbe. 2016 Jun 15. pii: S1931-3128(16)30207-4. doi: 10.1016/j.chom.2016.05.011. [Epub ahead of print]
[h=1]RIPK3 Activates Parallel Pathways of MLKL-Driven Necroptosis and FADD-Mediated Apoptosis to Protect against Influenza A Virus.[/h] Nogusa S[SUP]1[/SUP], Thapa RJ[SUP]1[/SUP], Dillon CP[SUP]2[/SUP], Liedmann S[SUP]2[/SUP], Oguin TH 3rd[SUP]2[/SUP], Ingram JP[SUP]1[/SUP], Rodriguez DA[SUP]2[/SUP], Kosoff R[SUP]1[/SUP], Sharma S[SUP]2[/SUP], Sturm O[SUP]2[/SUP], Verbist K[SUP]2[/SUP], Gough PJ[SUP]3[/SUP], Bertin J[SUP]3[/SUP], Hartmann BM[SUP]4[/SUP], Sealfon SC[SUP]4[/SUP], Kaiser WJ[SUP]5[/SUP], Mocarski ES[SUP]5[/SUP], L?pez CB[SUP]6[/SUP], Thomas PG[SUP]2[/SUP], Oberst A[SUP]7[/SUP], Green DR[SUP]8[/SUP], Balachandran S[SUP]9[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Influenza A virus (IAV) is a lytic virus in primary cultures of many cell types and in vivo. We report that the kinase RIPK3 is essential for IAV-induced lysis of mammalian fibroblasts and lung epithelial cells. Replicating IAV drives assembly of a RIPK3-containing complex that includes the kinase RIPK1, the pseudokinase MLKL, and the adaptor protein FADD, and forms independently of signaling by RNA-sensing innate immune receptors (RLRs, TLRs, PKR), or the cytokines type I interferons and TNF-α. Downstream of RIPK3, IAV activates parallel pathways of MLKL-driven necroptosis and FADD-mediated apoptosis, with the former reliant on RIPK3 kinase activity and neither on RIPK1 activity. Mice deficient in RIPK3 or doubly deficient in MLKL and FADD, but not MLKL alone, are more susceptible to IAV than their wild-type counterparts, revealing an important role for RIPK3-mediated apoptosis in antiviral immunity. Collectively, these results outline RIPK3-activated cytolytic mechanisms essential for controlling respiratory IAV infection.
Copyright ? 2016 Elsevier Inc. All rights reserved.


PMID: 27321907 [PubMed - as supplied by publisher]
 
Back
Top Bottom